CytoSorbents to Present at the OneMedForum 2013 Finance Conference

      CytoSorbents to Present at the OneMedForum 2013 Finance Conference

PR Newswire

MONMOUTH JUNCTION, N.J., Jan. 4, 2013

MONMOUTH JUNCTION, N.J., Jan. 4, 2013 /PRNewswire/ --CytoSorbents Corporation
(OTCBB: CTSO), a critical care focused company using blood purification to
treat life-threatening illnesses, announced that Dr. Phillip Chan, Chief
Executive Officer, will present at the OneMedForum 2013 Emerging Company
Finance Conference on Tuesday, January 8, 2013 in San Francisco at the Sir
Francis Drake Hotel. Dr. Chan's presentation will take place at 10:40AM PST
in the Windsor Room with a breakout session to follow.

A live video webcast will be available at
http://onemedplace.com/forum/webcast/ and will be available via archive after
the event.

About CytoSorbents, CytoSorb^®, and HemoDefend

CytoSorbents Corporation is a critical care focused therapeutic device company
using blood purification to modulate the immune system and fight multi-organ
failure in life-threatening illnesses. Its purification technology is based on
biocompatible, highly porous polymer beads that can actively remove toxic
substances from blood and other bodily fluids by pore capture and surface
adsorption. In 2011, CytoSorb^®, the Company's flagship product, achieved
European regulatory approval as an extracorporeal cytokine filter, allowing it
to be sold throughout the European Union (E.U.) under the CE Mark, to be used
in clinical situations where cytokines are elevated. The goal of the
CytoSorb^® cytokine filter is to reduce "cytokine storm" in critically-ill
patients that could otherwise lead to deadly inflammation, multiple organ
failure, immune dysfunction, and often death in common illnesses such as
sepsis, trauma, burn injury, acute respiratory distress syndrome, and
pancreatitis. The CytoSorb^® filter has demonstrated statistically significant
reductions in mortality in septic patients at high risk of death in early
studies and is now being sold in Germany, Austria and Switzerland for the
treatment of critical care illnesses, with availability in other E.U.
countries planned in the future, assuming adequate and timely funding, and
continued positive results from clinical studies.

HemoDefend is a development-stage blood purification technology platform for
the blood transfusion industry intended to reduce transfusion reactions and
safeguard the quality and safety of the blood supply. The HemoDefend
technology utilizes the Company's polymer bead technology to remove many
substances, such as antibodies, free hemoglobin and inflammatory mediators
that can cause potentially serious and sometimes fatal transfusion reactions.

CytoSorb^® and HemoDefend are just two of a number of different polymers the
Company has designed for various medical applications, including improved
dialysis, reduction of post-surgical complications in cardiac surgery,
treatment of inflammatory and autoimmune disorders, radio-imaging contrast
removal in imaging and interventional radiology procedures, and the treatment
of rhabdomyolysis, drug overdose, and others. Additional information is
available for download on the Company's website: http://www.cytosorbents.com.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for
the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this press
release are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ materially from
those anticipated. These statements are based on management's current
expectations and assumptions and are naturally subject to uncertainty and
changes in circumstances. We caution you not to place undue reliance upon any
such forward-looking statements. Actual results may differ materially from
those expressed or implied by the statements herein. CytoSorbents Corporation
and CytoSorbents, Inc believe that its primary risk factors include, but are
not limited to: obtaining government approvals including required FDA and
additional CE Mark approvals; ability to successfully develop commercial
operations; dependence on key personnel; acceptance of the Company's medical
devices in the marketplace; the outcome of pending and potential litigation;
compliance with governmental regulations; reliance on research and testing
facilities of various universities and institutions; the ability to obtain
adequate and timely financing in the future when needed; product liability
risks; limited manufacturing experience; limited marketing, sales and
distribution experience; market acceptance of the Company's products;
competition; unexpected changes in technologies and technological advances;
and other factors detailed in the Company's Form 10-K filed with the SEC on
March 30, 2012, which is available at http://www.sec.gov.

Contact:

CytoSorbents Corporation
Dr. Phillip Chan
Chief Executive Officer
(732) 329-8885 ext. *823
pchan@cytosorbents.com

SOURCE CytoSorbents Corporation

Website: http://onemedplace.com